Treace Medical Concepts, Inc.

NasdaqGS:TMCI Stock Report

Market Cap: US$483.4m

Treace Medical Concepts Valuation

Is TMCI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TMCI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TMCI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TMCI's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for TMCI?

Key metric: As TMCI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TMCI. This is calculated by dividing TMCI's market cap by their current revenue.
What is TMCI's PS Ratio?
PS Ratio2.5x
SalesUS$202.86m
Market CapUS$483.43m

Price to Sales Ratio vs Peers

How does TMCI's PS Ratio compare to its peers?

The above table shows the PS ratio for TMCI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.9x
SIBN SI-BONE
3.2x16.6%US$509.5m
OFIX Orthofix Medical
0.9x6.2%US$715.8m
AXGN Axogen
3.1x11.0%US$567.7m
SRDX Surmodics
4.4x11.7%US$559.1m
TMCI Treace Medical Concepts
2.5x8.2%US$483.4m

Price-To-Sales vs Peers: TMCI is good value based on its Price-To-Sales Ratio (2.5x) compared to the peer average (2.9x).


Price to Sales Ratio vs Industry

How does TMCI's PS Ratio compare vs other companies in the US Medical Equipment Industry?

52 CompaniesPrice / SalesEstimated GrowthMarket Cap
INGN Inogen
0.7x4.2%US$226.04m
ARAY Accuray
0.4x5.5%US$185.04m
NVRO Nevro
0.4x2.5%US$158.88m
KEQU Kewaunee Scientific
0.6xn/aUS$118.20m
TMCI 2.5xIndustry Avg. 3.2xNo. of Companies52PS02.85.68.411.214+
52 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: TMCI is good value based on its Price-To-Sales Ratio (2.5x) compared to the US Medical Equipment industry average (3.1x).


Price to Sales Ratio vs Fair Ratio

What is TMCI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TMCI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.5x
Fair PS Ratio2.7x

Price-To-Sales vs Fair Ratio: TMCI is good value based on its Price-To-Sales Ratio (2.5x) compared to the estimated Fair Price-To-Sales Ratio (2.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TMCI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$7.98
US$7.50
-6.0%
6.0%US$8.00US$7.00n/a5
Nov ’25US$4.78
US$7.10
+48.5%
9.3%US$8.00US$6.00n/a5
Oct ’25US$5.41
US$7.40
+36.8%
5.1%US$8.00US$7.00n/a5
Sep ’25US$6.17
US$7.50
+21.6%
5.4%US$8.00US$7.00n/a6
Aug ’25US$6.59
US$7.58
+15.1%
13.4%US$9.00US$6.00n/a6
Jul ’25US$6.49
US$6.83
+5.3%
13.8%US$8.00US$5.50n/a6
Jun ’25US$5.88
US$6.83
+16.2%
13.8%US$8.00US$5.50n/a6
May ’25US$10.86
US$15.86
+46.0%
8.5%US$18.00US$14.00n/a7
Apr ’25US$12.50
US$15.86
+26.9%
8.5%US$18.00US$14.00n/a7
Mar ’25US$13.42
US$15.86
+18.2%
8.5%US$18.00US$14.00n/a7
Feb ’25US$14.19
US$15.00
+5.7%
13.8%US$17.00US$11.00n/a7
Jan ’25US$12.75
US$14.57
+14.3%
15.1%US$17.00US$11.00n/a7
Dec ’24US$9.31
US$13.29
+42.7%
19.6%US$17.00US$10.00n/a7
Nov ’24US$10.10
US$23.57
+133.4%
27.5%US$31.00US$12.00US$4.787
Oct ’24US$13.11
US$28.50
+117.4%
7.2%US$31.00US$25.00US$5.416
Sep ’24US$15.57
US$28.50
+83.0%
7.2%US$31.00US$25.00US$6.176
Aug ’24US$21.92
US$30.50
+39.1%
6.2%US$33.00US$27.00US$6.596
Jul ’24US$25.58
US$30.50
+19.2%
6.2%US$33.00US$27.00US$6.496
Jun ’24US$26.51
US$30.50
+15.1%
6.2%US$33.00US$27.00US$5.886
May ’24US$26.03
US$30.17
+15.9%
7.3%US$33.00US$26.00US$10.866
Apr ’24US$25.19
US$29.75
+18.1%
1.5%US$30.00US$29.00US$12.504
Mar ’24US$21.05
US$29.25
+39.0%
2.8%US$30.00US$28.00US$13.424
Feb ’24US$23.50
US$29.25
+24.5%
2.8%US$30.00US$28.00US$14.194
Jan ’24US$22.99
US$28.50
+24.0%
3.9%US$30.00US$27.00US$12.754
Dec ’23US$24.67
US$28.50
+15.5%
3.9%US$30.00US$27.00US$9.314
Nov ’23US$23.46
US$30.00
+27.9%
13.5%US$37.00US$27.00US$10.104

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies